Maneuvering the Complex Web of Treatment Options for Relapsed/Refractory Multiple Myeloma
Clinicians face a difficult task of deciding who to treat, when to treat, and how to treat especially since many factors need to considered when determining the optimal multiple myeloma (MM) treatment for relapsed/refractory MM including: age, prognostic factors, comorbidities, toxicity profiles,
Category
  • Multiple Myeloma
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Patient Case Studies and Panel Discussion: Plasma Cell Neoplasms
As a result of the therapeutic advances and clinical research affecting the management of patients with cancer, clinicians can benefit by comparing their individual skills of diagnosis, treatment, and management of patients with their peers. This peer interaction is an integral part in enhancing clinical decision-making skills that can improve patient care.
Category
  • Plasma Cell Neoplasms
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Optimizing Treatment Approaches for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
The use of targeted therapies as a preferred treatment approach for newly diagnosed chronic lymphocytic leukemia (CLL) has significantly transformed the treatment landscape of relapsed/refractory disease. Clinicians are challenged to remain up-to-date about the recent clinical advances that can help them make informed clinical decisions for individual patients to optimize clinical outcomes.
Category
  • Chronic Lymphocytic Leukemia
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Minimal Residual Disease Assessment in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Is it Ready for Routine Clinical Practice?
There is a continuing need to educate clinicians about the current methods used for the detection of MRD and the prognostic significance of undetectable MRD in patients with CLL. This will also aid in the successful implementation of MRD testing when it becomes readily accessible for use in routine clinical setting.
Category
  • Chronic Lymphocytic Leukemia
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Updates in the Management of Early-Stage Diffuse Large B-Cell Lymphoma
Clinicians are challenged to remain up-to-date with the recent advances in the management of early stage DLBCL, and education will help them to make informed decisions in their routine clinical practice.
Category
  • Non-Hodgkin's Lymphoma
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Diffuse Large B-Cell Lymphoma: Optimizing Therapy for Relapsed/Refractory Disease
The advent of novel targeted therapies represents a major paradigm shift for management of relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Outcomes of relapsed/refractory DLBCL differ based on the response to initial therapy, timing of relapse, and opportunity to undergo transplant. A multidisciplinary approach is required for appropriate patient selection and the management of acute toxicities to prevent fatal outcomes.
Category
  • Non-Hodgkin's Lymphoma
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Patient Case Studies and Panel Discussion: Lymphomas
As a result of the therapeutic advances and clinical research affecting the management of patients with cancer, clinicians can benefit by comparing their individual skills of diagnosis, treatment, and management of patients with their peers. This peer interaction is an integral part in enhancing clinical decision-making skills that can improve patient care.
Category
  • Plasma Cell Neoplasms
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Mantle Cell Lymphoma: Updates in the Management of Relapsed/Refractory Disease
Treatment options should be individualized for patients with relapsed/refractory mantle cell lymphoma (MCL). The selection of optimal second-line therapy depends on the age and fitness of the patients as well as the eligibility for transplant. In the absence of standard management, patients with relapsed/refractory MCL, particularly those who are not eligible for transplant, should be referred for participation in prospective clinical trials investigating novel treatment regimens.
Category
  • Acute Myelogenous Leukemia
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Optimizing First-Line Therapy for Advanced Stage Classic Hodgkin Lymphoma
Recent studies are demonstrating the utility of novel agents and modifications to existing regimens as viable first-line options in early- and advanced-stage HL. An awareness of the clinical studies evaluating the utility of these treatment modalities will help oncology clinicians determine how to optimally incorporate them into the standard of care for patients and improve patient outcomes.
Category
  • Acute Myelogenous Leukemia
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Genetic/Familial Risk Assessment for Breast Cancer: Testing Considerations and Controversies
This program features world-renowned experts who will review the current standard of care for patients with breast cancer, the latest NCCN Guidelines recommendations, and recent clinical research updates.
Category
  • Breast Cancer
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation

Pages